Qiagen (QIA GY) appoints Pratt as CEO from September 1st. Reaffirms FY26 and Q3 guidance.

Leadership transitions of this kind, a named successor with a fixed start date and reaffirmed guidance in the same release, sit at the low-disruption end of the spectrum; the market's longstanding concern with CEO changes is strategic reset or guidance kitchen-sinking, and reaffirming the current year and the coming quarter explicitly forecloses the near-term version of that risk. The relevant distinction is between an internal continuity appointment and an external hire signalling strategic change; continuity cases have historically traded as non-events after the initial headline, while external arrivals at life sciences tools names have tended to precede portfolio reviews and capital allocation shifts. The reaffirmed guidance matters more than the personnel line, since incoming CEOs who intend to rebase expectations typically do so early, using the transition as cover. What is worth watching is the incoming CEO's first capital markets communication, any commentary on margin trajectory and M&A appetite, and whether the outgoing timeline implies a clean handover or an accelerated departure. Index membership keeps the name in passive flows regardless, so idiosyncratic signal will come from the strategy cues rather than the appointment itself.